文献速递MDS 与骨髓增殖性肿瘤

外周血患者状况多维评估与突变分析作为改善骨髓增生异常综合征预后预测的工具:西班牙MDS组的前瞻性研究

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
PubMed 文献 · Am J Hematol · 2017-07-19

该前瞻性队列纳入200例连续骨髓增生异常综合征(MDS)患者,按IPSS-R分层后评估Lee多维指数与二代测序突变分析的附加预测价值。结果显示,Lee指数可显著改善总生存预测(HR 3.02,95%CI 1.96-4.66,P<0.001),突变分析可显著改善白血病转化预测(HR 2.64,95%CI 1.56-4.46,P<0.001),非白血病死亡与患者状况强相关(HR 2.71,95%CI 1.72-4.25,P<0.001),而与IPSS-R评分(P=0.35)或突变状态(P=0.75)无关。

要点

  • 在IPSS-R基础上加入Lee指数可显著改善MDS患者总生存预测,HR 3.02(95%CI 1.96-4.66,P<0.001)。
  • 加入外周血突变分析可显著改善MDS患者白血病转化预测,HR 2.64(95%CI 1.56-4.46,P<0.001)。
  • 非白血病死亡与患者状况强相关(HR 2.71,95%CI 1.72-4.25,P<0.001),与IPSS-R评分(P=0.35)或突变状态(P=0.75)无关。

核心结论

  • 由Lee多维指数评估的患者状况及患者突变状态,可改善已按IPSS-R分层的MDS患者临床结局预测。

研究设计与样本

  • 西班牙MDS组开展的前瞻性队列研究,纳入2006年至2015年间200例连续MDS患者,按IPSS-R分类。
  • 患者进一步按患者状况(采用针对老年人的Lee多维指数评估)和基因突变(外周血样本经二代测序筛查)进行分层。
  • 在Cox模型中添加个体协变量后检验似然比变化。

主要发现

  • 将Lee指数加入IPSS-R可显著改善总生存预测(HR 3.02,95%CI 1.96-4.66,P<0.001)。
  • 突变分析可显著改善白血病演化预测(HR 2.64,95%CI 1.56-4.46,P<0.001)。
  • 非白血病死亡与患者状况强相关(HR 2.71,95%CI 1.72-4.25,P<0.001),但与IPSS-R评分(P=0.35)或突变状态(P=0.75)无关。
  • 以时间依赖协变量评估的疾病修饰治疗暴露校正对所提出模型的预测能力无影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The International Prognostic Scoring System and its revised form (IPSS-R) are the most widely used indices for prognostic assessment of patients with myelodysplastic syndromes (MDS), but can only partially account for the observed variation in patient outcomes. This study aimed to evaluate the relative contribution of patient condition and mutational status in peripheral blood when added to the IPSS-R, for estimating overall survival and the risk of leukemic transformation in patients with MDS. A prospective cohort (2006-2015) of 200 consecutive patients with MDS were included in the study series and categorized according to the IPSS-R. Patients were further stratified according to patient condition (assessed using the multidimensional Lee index for older adults) and genetic mutations (peripheral blood samples screened using next-generation sequencing). The change in likelihood-ratio was tested in Cox models after adding individual covariates. The addition of the Lee index to the IPSS-R significantly improved prediction of overall survival [hazard ratio (HR) 3.02, 95% confidence interval (CI) 1.96-4.66, P < 0.001), and mutational analysis significantly improved prediction of leukemic evolution (HR 2.64, 1.56-4.46, P < 0.001). Non-leukemic death was strongly linked to patient condition (HR 2.71, 1.72-4.25, P < 0.001), but not to IPSS-R score (P = 0.35) or mutational status (P = 0.75). Adjustment for exposure to disease-modifying therapy, evaluated as a time-dependent covariate, had no effect on the proposed model's predictive ability. In conclusion, patient condition, assessed by the multidimensional Lee index and patient mutational status can improve the prediction of clinical outcomes of patients with MDS already stratified by IPSS-R.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ramos F, Robledo C, Pereira A, et al. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. Am J Hematol. 2017. PMID: 28612357. doi:10.1002/ajh.24813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。